ArticleIBRO neuroscience reports2026
Investigation of cholecystokinin-8s-induced hypophagia in neonatal broiler chicks: Roles of central adrenergic and serotonergic systems.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholecystokinin (CCK) is integral to the central control of appetite, with its sulfated octapeptide isoform (CCK-8s) being particularly relevant. While CCK's anorexigenic effects have been established, the interactions between CCK-8s and adrenergic and serotonergic receptor subtypes in mediating food intake remain incompletely understood. This research was designed to examine the impact of centrally administered CCK-8s on food consumption in broilers, focusing on how it interacts with adrenergic and serotonergic receptors to influence intake. For this purpose, nine experiments were conducted on broilers. In experiment 1, broilers received central infusion of saline and CCK-8s (0.25, 0.5, and 1 nmol). The second experiment evaluated the effects of saline, the α1-adrenergic antagonist prazosin, CCK-8s at 1 nmol, and a combination of prazosin with CCK-8s. Experiments three through nine followed a similar design, substituting prazosin with other agents targeting different receptors, including the α2 antagonist yohimbine, β1 antagonist metoprolol, β2 antagonist ICI 118,551, serotonin synthesis inhibitor PCPA, serotonin reuptake inhibitor fluoxetine, 5-HT1A receptor agonist 8-OH-DPAT, and 5-HT2C receptor antagonist SB242084. Food intake was recorded cumulatively up to two hours after infusions. The outcomes demonstrated that CCK-8s (0.5 and 1 nmol) significantly decreased meal intake compared to controls (P < 0.05). Interestingly, administration of CCK-8s with fluoxetine significantly enhanced its appetite-suppressing effect (P < 0.05), whereas co-injections with SB242084, PCPA, or ICI 118,551 decreased this effect (P < 0.05). The data suggest that the anorexigenic influence of CCK-8s involves signaling pathways mediated by β2 adrenergic and 5-HT2C serotonergic receptors, offering fresh perspectives on neuropeptidergic regulation of feeding and highlighting the need for further detailed mechanistic studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.